- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04441333
Usability, Safety and Efficacy of AspivixTM
Usability, Safety and Efficacy of AspivixTM, an Atraumatic Innovative Uterine Cervical Traction Device: a Pilot Phase Followed by a Comparative Study (Pilot)
Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD). Currently, the available instruments are traumatic tenacula, which could cause pain and bleeding and therefore represent an obstacle for certain patients to pursue their medical follow-up.
AspivixTM is a new device, which enables atraumatic traction of the cervix while respecting its specific semi-circular anatomic shape through a system powered by a vacuum chamber.
The aim of our pilot study is to assess the usability, safety and efficacy of the device.
Note: Study is made of 2 phases (pilot phase followed by a comparative phase). Details regarding comparative study is registered separately.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- Department Women, Mother & Child, University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants older than 18 years
- Participants presenting at the outpatient clinic for Mirena IUD insertion.
- Participants able to provide informed consent as documented by signature with at least 24 hours of reflection time
- Good understanding of written and oral speaking used at the centre where the study will be carried out.
Exclusion Criteria:
- Participants who are contraindicated for the insertion of the IUD Mirena
- Participants under use of excessive alcohol, narcotics or benzodiazepines prior to procedure
- Participants who do not wish to be informed of a chance discovery
- Participant receiving anaesthetics prior to IUD insertion procedure
- Participants on anticoagulant medication
- Participants under use of an analgesic
- Previous cervical operation
- Severe vaginal bleeding
- Participant previously enrolled in this study
- Cervix diameter smaller than 26 mm
- Mullerian anomalies with two cervices
- Nabothian cyst
- Cervical myomas
- Cervical condylomas
- Squamous intraepithelial lesion (Cervical dysplasia)
- Cervical endometriosis
- Cervical tears
- A well exposed cervix and / or well aligned vaginal and cervical canals where no traction is required for IUD insertion
- Other cervical abnormalities (cervical polyp, cervical lesion, or irregularity) which may contraindicate or complicate IUD insertion
- Large ectopy, for which it is not possible to find a suitable location near the ectopy where native tissue is present
- Large scar tissue, for which it is not possible to find a suitable location near the scar where native tissue is present
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AspivixTM cervical vacuum tenaculum
Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum.
|
Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Usability and efficacy from the practitioner's perspective: questionnaire
Time Frame: Right after the use of the device (right after the end of the procedure to insert the IUD).
|
The practitioner will assess the usability and efficacy of the Investigational Device using a 5 point Likert 'Usability and Efficacy Questionnaire'.
|
Right after the use of the device (right after the end of the procedure to insert the IUD).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of bleeding
Time Frame: During the procedure to insert the IUD which should last less than 5 minutes.
|
To assess bleeding, every buffer will be weighted, and the blank weight subtracted.
Weight in mg will be reported in the case report form.
|
During the procedure to insert the IUD which should last less than 5 minutes.
|
Assessment of adverse events
Time Frame: During the procedure to insert the IUD which should last less than 5 minutes.
|
Safety of the procedure will be assessed by documenting adverse events (description of the adverse events, number of participants)
|
During the procedure to insert the IUD which should last less than 5 minutes.
|
Identification of new risks
Time Frame: During the procedure to insert the IUD which should last less than 5 minutes.
|
Safety of the procedure will be assessed by identifying and documenting any new risk.
|
During the procedure to insert the IUD which should last less than 5 minutes.
|
Participant's reported pain: Visual Analogue Scale
Time Frame: Before the procedure, during speculum insertion, during AspivixTM vacuum application, during application of cervical traction, during IUD insertion, during AspivixTM release, 5 minutes after the end of the procedure
|
Participant's reported pain will be assessed by the patient using a 100-point Visual Analogue Scale (VAS) at specific steps during IUD insertion Minimum and maximum values range from 0 to 100, the higher score being the better outcome.
|
Before the procedure, during speculum insertion, during AspivixTM vacuum application, during application of cervical traction, during IUD insertion, during AspivixTM release, 5 minutes after the end of the procedure
|
Assessment of patient's satisfaction: questionnaire
Time Frame: Right after the use of the device (right after the end of the procedure to insert the IUD).
|
5 point Likert 'Patient Satisfaction Questionnaire' Minimal to maximal values range from 1 to 5, 1 meaning "disagree" and 5 "agree".
|
Right after the use of the device (right after the end of the procedure to insert the IUD).
|
The number of placement attempts before traction can be applied
Time Frame: During the procedure to insert the IUD which should last less than 5 minutes.
|
The number of placement attempts before traction of the cervix can be applied will be recorded
|
During the procedure to insert the IUD which should last less than 5 minutes.
|
The number of spontaneous releases during traction
Time Frame: During the procedure to insert the IUD which should last less than 5 minutes.
|
The number of spontaneous releases during traction of the cervix will be recorded
|
During the procedure to insert the IUD which should last less than 5 minutes.
|
Assessment of device deficiencies
Time Frame: During the procedure to insert the IUD which should last less than 5 minutes.
|
Safety of the procedure will be assessed by documenting device deficiencies (description of the deficiency)
|
During the procedure to insert the IUD which should last less than 5 minutes.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Aspivix_IUD2019_Pilot
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IUD Insertion
-
University of California, DavisRecruiting
-
Ain Shams UniversityCompleted
-
Ain Shams UniversityRecruiting
-
Aspivix SACompleted
-
Assiut UniversityCompleted
-
University of SaskatchewanRecruitingIUD Insertion ComplicationCanada
-
Thomas Jefferson UniversityRecruiting
-
Ain Shams UniversityUnknownIUD Insertion ComplicationEgypt
-
The University of Texas Health Science Center,...CompletedAnalgesia | IUD InsertionUnited States
-
Cairo UniversityCompletedIUD Insertion ComplicationEgypt
Clinical Trials on AspivixTM cervical vacuum tenaculum
-
IRCCS Burlo GarofoloCompleted
-
Wake Forest University Health SciencesCompleted
-
Shima Abdollah Mohammad ZadehNot yet recruitingTemporomandibular Disorder | Forward Head PostureUnited Arab Emirates